Management of sialorrhoea in motor neuron disease: A survey of current UK practice

References

• Bradley WG, Anderson F, Bromberg M, Gutmann L, Harati Y, Ross M, et al. Current management of ALS: comparison of the ALS CARE Database and the AAN Practice Parameter. The American Academy of Neurology. Neurology. 2001;57: 500–4.
   PubMed Web of Science ®Google Scholar
• Young CA, Ellis C, Johnson J, Sathasivam S, Pih N. Treatment for sialorrhoea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis. Cochrane Database Syst Rev. 2011;5:CD006981.
   Google Scholar
• Newall AR, Orser R, Hunt M. The control of oral secretions in bulbar ALS/MND. J Neurol Sci. 1996;139 (Suppl): 43–4.
   PubMed Web of Science ®Google Scholar
• Oliver D. The quality of care and symptom control: the effects on the terminal phase of ALS/MND. J Neurol Sci. 1996;139 (Suppl):134–6.
   PubMed Web of Science ®Google Scholar
• Reddihough D, Erasmus CE, Johnson H, McKellar GMW, Jongerius PH. Botulinum toxin assessment, intervention and aftercare for paediatric and adult drooling: international consensus statement. Eur J Neurol. 2010;17:109–21.
   PubMed Web of Science ®Google Scholar
• Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Eng J Med. 2001;344:1688–700.
   PubMed Web of Science ®Google Scholar
• Peysson S, Vandenberghe N, Philit F, Vial C, Petitjean T, Bouhour F, et al. Factors predicting survival following non-invasive ventilation in amyotrophic lateral sclerosis. Eur Neurol. 2008;59:164–71.
   PubMed Web of Science ®Google Scholar
• Miller RG, Jackson CE, Kasarskis EJ, England JD, Forshew D, Johnston W, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis. Multidisciplinary care, symptom management, and cognitive/behavioural impairment (an evidence based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009;73:1227–33.
   PubMed Web of Science ®Google Scholar
• Andersen PM, Abrahams S, Borasio GD, de Carvalho M, Chio A, van Damme P, et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS): revised report of an EFNS task force. Eur J Neurol. 2012; 19:360–75.
   PubMed Web of Science ®Google Scholar
• Guidubaldi A, Fasano A, Ialongo T, Piano C, Pompili M, Mascianà R, et al. Botulinum toxin A versus B in sialorrhoea: a prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson’s disease. Mov Disord. 2011;26:313–9.
   PubMed Web of Science ®Google Scholar
• Jackson CE, Gronseth G, Rosenfeld J, Barohn RJ, Dubinsky R, Simpson CB, et al. Randomized double-blind study of botulinum toxin type B for sialorrhoea in ALS patients. Muscle Nerve. 2009;39:137–43.
   PubMed Web of Science ®Google Scholar
• Rosales RL, Bigalke H, Dressler D. Pharmacology of botulinum toxin: differences between type A preparations. Eur J Neurol. 2006;13 (Suppl 1):2–10.
   PubMed Web of Science ®Google Scholar
• Tan E-K. Botulinum toxin treatment of sialorrhoea: comparing different therapeutic preparations. Eur J Neurol. 2006;13 (Suppl 1):60–4.
   PubMed Web of Science ®Google Scholar
• Burgen ASV, Dickens F, Zatman LJ. The action of botulinum toxin on the neuromuscular junction. The Journal of Physiology. 1949;109:10–24.
   PubMed Web of Science ®Google Scholar
• Andersen PM, Grönberg H, Franzen L, Funegård U. External radiation of the parotid glands significantly reduces drooling in patients with motor neuron disease with bulbar paresis. J Neurol Sci. 2001;191:111–4.
   PubMed Web of Science ®Google Scholar
• Guy N, Bourry N, Dallel R, Dualé C, Verrelle P, Lapeyre M, et al. Comparison of radiotherapy types in the treatment of sialorrhoea in amyotrophic lateral sclerosis. J Palliat Med. 2011;14:391–5.
   PubMed Web of Science ®Google Scholar
• Harriman M, Morrison M, Hay J, Revonta M, Eisen A, Lentle B. Use of radiotherapy for control of sialorrhoea in patients with amyotrophic lateral sclerosis. The Journal of Otolaryngology. 2001;30:242–5.
   PubMedGoogle Scholar
• Neppelberg E, Haugen DF, Thorsen L, Tysnes O-B. Radiotherapy reduces sialorrhoea in amyotrophic lateral sclerosis. Eur J Neurol. 2007;14:1373–7.
   PubMed Web of Science ®Google Scholar
• Martin TJ, Conley SF. Long-term efficacy of intra-oral surgery for sialorrhoea. Otolaryngology – head and neck surgery: official journal of American Academy of Otolaryngology-Head and Neck Surgery. 2007;137: 54–8.
   Google Scholar
• Oliveira RS, Resende C, Campos J, Salgado C. Surgical approach to sialorrhoea: a casuistic review and evaluation of grade of satisfaction. Cir Pediatr. 2010;23:211–4.
   PubMedGoogle Scholar
• Stamataki S, Behar P, Brodsky L. Surgical management of drooling: clinical and caregiver satisfaction outcomes. Int J Pediatr Otorhinolaryngol. 2008;72:1801–5.
   PubMed Web of Science ®Google Scholar
• Blackhall LJ. Amyotrophic lateral sclerosis and palliative care: where we are, and the road ahead. Muscle Nerve. 2012;45:311–8.
   PubMed Web of Science ®Google Scholar
• Walshe M, Smith M, Pennington L. Interventions for drooling in children with cerebral palsy. Cochrane Database Syst Rev. 2012;2:CD008624.
   Google Scholar
• Chou KL, Evatt M, Hinson V, Kompoliti K. Sialorrhea in Parkinson’s disease: a review. Mov Disord. 2007;22: 2306–13.
   PubMed Web of Science ®Google Scholar
• Perez Lloret S, Pirán Arce G, Rossi M, Caivano Nemet ML, Salsamendi P, Merello M. Validation of a new scale for the evaluation of sialorrhoea in patients with Parkinson’s disease. Mov Disord. 2007;22:107–11.
   PubMed Web of Science ®Google Scholar
• Abdelnour-Mallet M, Tezenas Du Montcel S, Cazzolli PA, Assouline A, Pointon C, Leveque N, et al. Validation of robust tools to measure sialorrhoea in amyotrophic lateral sclerosis: a study in a large French cohort. Amyotroph Lateral Scler. 2013;14:302–307.
   PubMed Web of Science ®Google Scholar
• Hopcutt B, Alnufoury H. Sialorrhoea treatment algorithm for MND. Available from: www.mndassociation.org/for-professionals/sharing-good-practice/care-pathway-and-clinical-guideline-examples.htm.
   Google Scholar
• Abhinav K, Stanton B, Johnston C, Hardstaff J, Orrell RW, Howard R, et al. Amyotrophic lateral sclerosis in south-east England: a population based study. The South-East England Register for Amyotrophic Lateral Sclerosis (SEALS registry). Neuroepidemiology. 2007;29:44–8.
   PubMed Web of Science ®Google Scholar
• PatientsLikeMe. What we have learned from patients with ALS (amyotropic lateral sclerosis) who report excess saliva. 2012; Available from: www.PatientsLikeMe.com.
   Google Scholar
• Meijer J-WG, van Kuijk AA, Geurts ACH, Schelhaas HJ, Zwarts MJ. Acute deterioration of bulbar function after botulinum toxin treatment for sialorrhoea in amyotrophic lateral sclerosis. Am J Phys Med Rehabil. 2008;87: 321–4.
   PubMed Web of Science ®Google Scholar
• Tan E-K, Lo YL, Seah A, Auchus AP. Recurrent jaw dislocation after botulinum toxin treatment for sialorrhoea in amyotrophic lateral sclerosis. J Neurol Sci. 2001;190: 95–7.
   PubMed Web of Science ®Google Scholar
• Haverkamp LJ, Appel V, Appel SH. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain. 1995;118:707–19.
   Google Scholar
• O’Neill CL, Williams TL, Peel ET, McDermott CJ, Shaw PJ, Gibson GJ, et al. Non-invasive ventilation in motor neuron disease: an update of current UK practice. J Neurol Neurosurg Psychiatry. 2012;83:371–6.
   PubMed Web of Science ®Google Scholar